Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX۴

Publish Year: 1394
نوع سند: مقاله ژورنالی
زبان: English
View: 73

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MISJ-6-3_006

تاریخ نمایه سازی: 25 آبان 1402

Abstract:

Background: Over the past decade, survival from advanced colorectal cancer is increasing. Therefore patients have more exposure to chemotherapy and related toxicities. This study determines how hematologic toxicity patterns affect therapy and care.Methods: From April ۲۰۱۰ to March ۲۰۱۳, we enrolled ۱۲۷ patients with stages IIb to IV colorectal cancer. Patients underwent complete blood count monitoring prior to and during each cycle of FOLFOX۴ chemotherapy. Granulocyte colony stimulating factor was injected if their white blood cells were below ۳.۵×۱۰۹/L.Results: The most common hematologic toxicities were grades ۱-۲ for hemoglobin (۷۶.۸۳%) and leukopenia (۲۶.۴۸%). The least common hematologic toxicity was thrombocytopenia (۴.۶۹%) for all grades of platelet toxicity. The median granulocyte colony stimulating factor injection was ۳.۳۳ per ۱۲ cycles.Conclusion: Anemia and leukopenia are the most common hematologic abnormalities expected with FOLFOX۴ chemotherapy regimens for colorectal cancer. The most important factor for predicting hematologic toxicities in patients who receive chemotherapy for colorectal cancer is the number of chemotherapy cycles.

Authors

Mehdi Dehghani

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Nematollah Hafezi

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Reza Vojdani

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Mani Ramzi

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Mojtaba Karimi

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Habib Nourani

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Maryam Zakerinia

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Zahra Bahador

Department of Hematology and Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran